Taxus Cardium Pharmaceuticals Group Inc  

(Public, OTCMKTS:CRXM)   Watch this stock  
Find more results for NYSEAMEX:CXM
0.000 (0.00%)
Delayed:   11:00AM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.17 - 0.18
52 week 0.07 - 0.63
Open 0.18
Vol / Avg. 9,186.00/9,891.00
Mkt cap 2.30M
P/E     -
Div/yield     -
EPS -0.39
Shares 12.78M
Beta 2.83
Inst. own 10%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -377.06% -311.71%
Return on average equity - -
Employees 11 -
CDP Score - -


11750 Sorrento Valley Rd Ste 250
SAN DIEGO, CA 92121-1061
United States - Map
+1-858-4361000 (Phone)
+1-302-6365454 (Fax)

Website links


Taxus Cardium Pharmaceuticals Group Inc. (Taxus Cardium) is a regenerative medicine biotechnology company. The Company is focused on the development of advanced regenerative therapeutics designed to promote the activation and growth of microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and granulation tissue as a treatment for chronic non-healing wounds. Its product Generx (alferminogene tadenovec) is an adenovector (serotype 5) Deoxyribonucleic acid (DNA) based gene therapy construct that encodes the Fibroblast Growth Factor-4 (FGF-4) gene. Its product Excellagen is a pharmaceutically formulated acellular biological modulator that is engineered to activate and promote wound healing. The Company's subsidiaries include Angionetics Inc., Activation Therapeutics, Inc. and LifeAgain Insurance Solutions, Inc, among others.

Officers and directors

Christopher J. Reinhard Chairman of the Board, President, Chief Executive Officer, Treasurer
Age: 61
Gabor M. Rubanyi M.D., Ph.D. Chief Scientific Officer
Age: 68
Tyler M. Dylan-Hyde J.D., Ph.D. Director
Age: 54
John F. Wallace Director
Age: 65
Jiayue Zhang Director
Age: 56
Wei-Wei Zhang Ph.D., M.D. Director
Age: 57
Edward W. Gabrielson M.D. Independent Director
Age: 62